OA11484A - Biphasic controlled release delivery system for high solubility pharmaceuticals and method. - Google Patents

Biphasic controlled release delivery system for high solubility pharmaceuticals and method. Download PDF

Info

Publication number
OA11484A
OA11484A OA1200000242A OA1200000242A OA11484A OA 11484 A OA11484 A OA 11484A OA 1200000242 A OA1200000242 A OA 1200000242A OA 1200000242 A OA1200000242 A OA 1200000242A OA 11484 A OA11484 A OA 11484A
Authority
OA
OAPI
Prior art keywords
phase
metformin
pharmaceutical
solid
drug
Prior art date
Application number
OA1200000242A
Other languages
English (en)
Inventor
Peter Timmins
Andrew B Dennis
Kiren A Vyas
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21932435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11484(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of OA11484A publication Critical patent/OA11484A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA1200000242A 1998-03-19 2000-09-05 Biphasic controlled release delivery system for high solubility pharmaceuticals and method. OA11484A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4444698A 1998-03-19 1998-03-19

Publications (1)

Publication Number Publication Date
OA11484A true OA11484A (en) 2004-05-03

Family

ID=21932435

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000242A OA11484A (en) 1998-03-19 2000-09-05 Biphasic controlled release delivery system for high solubility pharmaceuticals and method.

Country Status (14)

Country Link
US (2) US6475521B1 (fr)
EP (2) EP1063973B1 (fr)
JP (1) JP4523153B2 (fr)
KR (1) KR100620935B1 (fr)
CN (1) CN1203846C (fr)
AP (1) AP1224A (fr)
AU (1) AU736951C (fr)
BR (1) BR9908911A (fr)
CA (1) CA2320900C (fr)
EA (1) EA003101B1 (fr)
ID (1) ID26082A (fr)
NZ (1) NZ506202A (fr)
OA (1) OA11484A (fr)
WO (1) WO1999047128A1 (fr)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
WO1999029314A1 (fr) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Sels de metformine et procede
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
WO2001035940A2 (fr) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Nouvelle composition et utilisation
CA2396782A1 (fr) 2000-02-04 2001-08-09 Depomed, Inc. Forme posologique enveloppe et noyau approchant la liberation d'ordre zero du medicament
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
AU2001213150A1 (en) * 2000-08-03 2002-02-18 Olga Evgenievna Kolesova Composition of metformin with succinic acid or salts thereof and method for treating diabetes
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
EP1322158B1 (fr) * 2000-10-02 2012-08-08 USV Ltd. Compositions pharmaceutiques a liberation prolongee contenant de la metformine, procedes de production de ces dernieres
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
WO2002036100A1 (fr) 2000-11-03 2002-05-10 Andrx Corporation Compositions de metformine a liberation controlee
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2818906B1 (fr) * 2000-12-29 2004-04-02 Dospharma Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
CA2434169C (fr) * 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Systeme de liberation espacee de medicaments
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
MXPA03008997A (es) * 2001-04-10 2004-02-12 Sun Pharmaceutical Ind Ltd Composicion de liberacion por impulso temporizado.
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
CA2445086C (fr) 2001-05-01 2008-04-08 A.V. Topchiev Institute Of Petrochemical Synthesis Compositions d'hydrogel
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
FR2825023B1 (fr) 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
WO2003004009A1 (fr) * 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Formulation a compression directe de medicaments faiblement compressibles tels que le chlorhydrate de metformine
MXPA03012041A (es) * 2001-07-04 2004-03-26 Sun Pharmaceutical Ind Ltd Sistema de administracion controlada de farmacos de retencion gastrica.
JP2005525299A (ja) * 2001-09-14 2005-08-25 スコラー インコーポレイテッド アミノ酸調節性の長期放出投薬形態
IN192180B (fr) * 2001-09-28 2004-03-06 Ranbaxy Lab
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
EA200400628A1 (ru) * 2001-11-06 2004-12-30 Рэнбакси Лабораториз Лимитед Таблетки метформина с контролируемым высвобождением активного компонента
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
MXPA04006522A (es) * 2002-01-04 2004-10-04 Ivax Research Inc Sistema de suministro de medicamentos para el suministro sostenido de glipizida.
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8323692B2 (en) * 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
IL149055A0 (en) * 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
KR20050005437A (ko) 2002-04-09 2005-01-13 플라멜 테크놀로지스 아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제
WO2003099214A2 (fr) * 2002-05-23 2003-12-04 Andrx Corporation Formulations de biguanide
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AU2003261298A1 (en) 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20050048119A1 (en) * 2002-09-20 2005-03-03 Avinash Nangia Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
ES2529180T3 (es) 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
CA2507685A1 (fr) * 2002-11-28 2004-06-10 Themis Laboratories Private Limited Procede de fabrication de microperles a liberation prolongee contenant de la venlafaxine hci
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
CA2453013C (fr) 2002-12-13 2011-02-15 Gary W. Cleary Dispositifs d'administration d'ingredients par voie percutanee, transdermique ou transmuqueuse ou par les muqueuses
DE10260921A1 (de) * 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zum Überziehen von Substraten für pharmazeutische Anwendungen mit einem Gemisch aus zwei filmbildenden Überzugsmitteln
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
CN100500130C (zh) * 2003-01-23 2009-06-17 株式会社太平洋 缓释制剂及其制备方法
US7976853B2 (en) 2003-01-29 2011-07-12 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
US7888546B2 (en) 2003-07-03 2011-02-15 Corium International, Inc. Wound dressing, ingredient delivery device and IV hold-down, and method relating to same
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
ES2328579T3 (es) * 2003-07-25 2009-11-16 Conjuchem Biotechnologies Inc. Derivados de insulina de larga duracion y procedimientos asociados.
AP1899A (en) 2003-08-08 2008-10-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
EP1510208A1 (fr) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Compositions pharmaceutiques comprenant une combinaison de metformine et de statine
DE10359792A1 (de) * 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Mehrphasige Wirkstoffformulierung
JP2007516294A (ja) * 2003-12-23 2007-06-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 炎症性の疾患または症状の予防および治療のための方法および組成物
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
WO2005065654A2 (fr) * 2003-12-31 2005-07-21 Alpharma, Inc. Preparations de rosiglitazone
EP1559419A1 (fr) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Composition pharmaceutique contenant une combinaison de mefformine et d'un fibrate et les procédés pour les obtenir
RU2380092C2 (ru) 2004-01-30 2010-01-27 Кориум Интернэшнл, Инк. Быстро растворяющаяся пленка для доставки активного агента
EP1734953A4 (fr) * 2004-03-02 2008-08-20 Abeille Pharmaceuticals Inc Co-pr parations de kits d'agents bioacitfs
WO2005092293A1 (fr) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Formulations de metformine
CA2562391A1 (fr) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Preparation pharmaceutique solide
RS20060605A (en) * 2004-04-29 2008-09-29 Caldwell Galer Inc., Topical methadone compositions and methods for using the same
TR201819108T4 (tr) * 2004-06-10 2019-01-21 Glatt Air Techniques Inc Kontrollü salımlı matrisli farmasötik dozaj formülasyonu.
US20050285732A1 (en) * 2004-06-25 2005-12-29 Sengupta Uttam K Radio frequency identification based system to track consumption of medication
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
EP1791575B1 (fr) 2004-08-05 2014-10-08 Corium International, Inc. Composition d'adhesif
EP1814528A2 (fr) * 2004-10-08 2007-08-08 Rubicon Research Private Limited Procede pour fabriquer des compositions fortement compressible a delivrance controllee de metformine
EP1812920A1 (fr) * 2004-10-29 2007-08-01 Adhesives Research, Inc. Systeme de marquage microscopique pour une identification securisee
US8012374B2 (en) * 2004-11-04 2011-09-06 The University Of Cincinnati Slow-release inhibitor for corrosion control of metals
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
AP2244A (en) * 2005-04-26 2011-06-24 Caldwell Galer Inc Topical methadone compositions and methods for using the same.
WO2006123213A1 (fr) * 2005-05-18 2006-11-23 Ranbaxy Laboratories Limited Preparations a liberation modifiee de gliclazide
US20060275249A1 (en) * 2005-06-03 2006-12-07 Jones Michael R Co-therapy for diabetic conditions
JPWO2007010847A1 (ja) * 2005-07-15 2009-01-29 キッセイ薬品工業株式会社 徐放製剤
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
US20070077305A1 (en) * 2005-10-03 2007-04-05 Le Tien C Biocompatible polymeric matrix and preparation thereof
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP1991210A1 (fr) * 2006-02-15 2008-11-19 Intec Pharma Ltd. Système de gastro-rétention pour dé livrer des macromolécules
JP5826456B2 (ja) 2006-04-26 2015-12-02 アルファファーム ピーティーワイ リミテッド コーティングされていない分離したユニットおよび延長放出マトリクスを含む制御放出配合物
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
US20080095856A1 (en) * 2006-05-12 2008-04-24 Jacobson Gunilla B Encapsulated Nanoparticles for Drug Delivery
CZ300698B6 (cs) * 2006-06-16 2009-07-22 Zentiva, A. S. Tableta s obsahem metforminu
WO2008003093A2 (fr) * 2006-06-29 2008-01-03 Questcor Pharmaceuticals, Inc. Compositions pharmaceutiques et procédés de traitement apparentés
KR100791844B1 (ko) * 2006-06-30 2008-01-07 주식회사유한양행 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법
WO2008051902A2 (fr) 2006-10-20 2008-05-02 Cpd, Llc Procédé pour rétablir l'effet de l'incrétine
CN105152983A (zh) 2007-01-29 2015-12-16 韩诺生物制药株式会社 N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
KR101381999B1 (ko) * 2007-07-06 2014-04-14 동아에스티 주식회사 위염 치료제의 효력을 극대화시키기 위한 가용화 위체류시스템 매트릭스 제제
WO2009035969A1 (fr) * 2007-09-10 2009-03-19 Janssen Pharmaceutica N.V. Procédé pour la préparation de composés utiles en tant qu'inhibiteurs de sglt
KR101226669B1 (ko) * 2007-09-21 2013-01-25 한올바이오파마주식회사 Ｎ,ｎ－디메틸 이미도디카르본이미딕 디아미드의 디카르복실산염, 그의 제조 방법 및 그의 약제학적 조성물
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8303573B2 (en) 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8333754B2 (en) * 2007-10-31 2012-12-18 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8109920B2 (en) * 2007-10-31 2012-02-07 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
EP2244789A2 (fr) * 2008-01-16 2010-11-03 Janssen Pharmaceutica NV Combinaison de metformine et inhibiteur mtp
JP2011510986A (ja) * 2008-02-05 2011-04-07 メルク・シャープ・エンド・ドーム・コーポレイション メトホルミン及びジペプチジルペプチダーゼ−ｉｖ阻害剤の併用医薬組成物
EP2259676A4 (fr) * 2008-03-04 2011-03-16 Merck Sharp & Dohme Compositions pharmaceutiques d'une combinaison de metformine et d'un inhibiteur de dipeptidyl peptidase-iv
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
CA2638240C (fr) * 2008-08-29 2010-02-02 Alexander Macgregor Methode de traitement des anomalies de la glycemie et des variations de la glycemie
WO2010026467A2 (fr) 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Forme pharmaceutique à libération prolongée de principe actif hautement soluble
US20100068256A1 (en) 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-substance
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
EP2181705A1 (fr) 2008-10-31 2010-05-05 Disphar International B.V. Formulation à libération prolongée de gliclazide
US8784879B2 (en) 2009-01-14 2014-07-22 Corium International, Inc. Transdermal administration of tamsulosin
EP2403487A2 (fr) * 2009-03-04 2012-01-11 Fdc Limited Nouvelles formes galéniques orales à libération contrôlée pour médicaments hydrosolubles
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (fr) 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. Procédé de cristallisation pour le 1-(bêta -D-glucopyranosyl)-4-méthyl-3-[5-(4-fluorophényl)-2-thiènylméthyl] benzène
US20120135952A1 (en) * 2009-07-17 2012-05-31 Hanall Biopharma Co., Ltd. Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same
WO2011008053A2 (fr) * 2009-07-17 2011-01-20 한올바이오파마주식회사 Propionate de n,n-diméthyl diamide imidocarbonimidique, son procédé de préparation ainsi que compositions et combinaisons pharmaceutiques le contenant
WO2011047113A1 (fr) * 2009-10-14 2011-04-21 Janssen Pharmaceutica Nv Procédé de préparation de composés utiles comme inhibiteurs de sglt2
RU2564901C2 (ru) * 2009-11-13 2015-10-10 Бристол-Майерс Сквибб Кампани Композиции метформина с уменьшенной массой
CA2780939C (fr) * 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Formulations de comprime bicouche
WO2011061616A2 (fr) * 2009-11-23 2011-05-26 Micro Labs Limited Compositions à libération prolongée contenant de la toltérodine et procédé de préparation de celles-ci
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
CN108354930A (zh) 2010-05-11 2018-08-03 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
WO2011159824A1 (fr) 2010-06-16 2011-12-22 Allergan, Inc. Composition et méthode de traitement d'une vessie hyperactive
TWI541030B (zh) * 2010-07-06 2016-07-11 健生藥品公司 用於糖尿病協同治療之調配物
MX342120B (es) * 2010-07-09 2016-09-14 William Owen Wilkison Combinación de sistema de liberación prolongada/inmediata para productos farmacéuticos de vida media corta como el remogliflozin.
EP2611434A1 (fr) * 2010-09-01 2013-07-10 Lupin Limited Composition pharmaceutique contenant de la metformine et de la pioglitazone
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CA2823397C (fr) 2011-01-07 2020-03-10 Elcelyx Therapeutics, Inc. Traitements a base de ligand de recepteur chimiosensoriel
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
HUE030116T2 (en) 2011-04-13 2017-04-28 Janssen Pharmaceutica Nv A method for preparing compounds useful as inhibitors of SGLT2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
ES2586057T3 (es) * 2011-07-26 2016-10-11 Yuhan Corporation Comprimido de liberación sostenida que comprende pregabalina a través de un sistema de control de la liberación de dos fases
KR20190120430A (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
AU2013207329B2 (en) 2012-01-06 2017-10-26 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2638898A1 (fr) 2012-03-16 2013-09-18 Sanovel Ilac Sanayi ve Ticaret A.S. Formulation de pioglitazone et metformine avec différents profils de libération
DE102012102414A1 (de) * 2012-03-21 2013-10-10 Michael Dittgen Pharmazeutische Zusammensetzung für die einmal tägliche Anwendung antidiabetischer Arzneimittel wie Metformin mit Zwei-Puls-Freisetzung
WO2014014427A1 (fr) 2012-07-16 2014-01-23 Mahmut Bilgic Formulations de comprimés pharmaceutiques à libération modifiée
US20140037816A1 (en) * 2012-07-31 2014-02-06 Hercules Incorporated Stabilized multiphase aqueous compositions
WO2014154643A1 (fr) * 2013-03-25 2014-10-02 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations de metformine à libération prolongée
US20150374688A1 (en) 2013-03-26 2015-12-31 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof.
EP2996680A1 (fr) 2013-03-28 2016-03-23 Wockhardt Limited Compositions pharmaceutiques orales solides comprenant une combinaison de doses fixes de metformine et de sitagliptine ou de leurs sels
KR101751631B1 (ko) * 2013-05-31 2017-06-27 히사미쓰 세이야꾸 가부시키가이샤 구강 첩부제
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
US20170049705A1 (en) * 2014-04-29 2017-02-23 Matripharm Inc. Monolithic tablets based on carboxyl polymeric complexes for controlled drug release
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
US10034871B2 (en) 2014-11-07 2018-07-31 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
MA39929A (fr) 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret As Comprimé multicouche comprenant de la metformine et du pioglitazone
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CA3001337C (fr) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Formulation pharmaceutique
IL261756B2 (en) 2016-03-17 2023-11-01 Thiogenesis Therapeutics Inc Preparations for the controlled release of cysteamine and systemic treatment of disorders sensitive to cysteamine
TR201620309A2 (tr) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
WO2019018155A1 (fr) 2017-07-17 2019-01-24 Eli Lilly And Company Compositions pharmaceutiques
WO2019018158A1 (fr) 2017-07-17 2019-01-24 Eli Lilly And Company Compositions pharmaceutiques
CN110996925A (zh) * 2017-08-02 2020-04-10 南洋理工大学 可漂浮的药物微胶囊组合物
JP7208982B2 (ja) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド システアミン感受性障害の治療方法
CN114191307A (zh) 2020-09-17 2022-03-18 上海汉都医药科技有限公司 一种口腔滞留装置及其制备方法
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
CN112118886B (zh) 2018-05-23 2022-08-23 上海汉都医药科技有限公司 活性药物成分的控释系统及其制备方法
MX2020013654A (es) 2018-06-19 2021-03-25 Nat Univ Singapore Formulaciones de 5-hidroxitriptofano (5-htp) para mejor biodisponibilidad para diversas indicaciones.
CN110354090B (zh) * 2019-07-29 2021-10-01 石药集团欧意药业有限公司 一种盐酸二甲双胍缓释片及其制备方法
CN114302712B (zh) * 2019-09-04 2023-08-04 鲁南贝特制药有限公司 一种阿昔莫司多单元缓释微丸片及其制备方法
US20210403660A1 (en) * 2020-06-30 2021-12-30 Fujifilm Business Innovation Corp. Biodegradable resin particle
AU2022320730A1 (en) 2021-07-30 2024-03-14 Evecxia Therapeutics, Inc. 5-hydroxytryptophan gastroretentive dosage forms
CN113662940B (zh) * 2021-09-02 2023-03-24 福州大学 一种盐酸二甲双胍和TGF-β抑制剂自组装的纳米材料
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
IT202100031691A1 (it) 2021-12-17 2023-06-17 I B N Savio S R L Processo produttivo di compresse a rilascio sostenuto di metformina
CN114404376A (zh) * 2022-03-16 2022-04-29 成都恒瑞制药有限公司 一种盐酸二甲双胍缓释片剂及其制备方法
EP4385502A1 (fr) 2022-12-15 2024-06-19 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulation pharmaceutique comprenant de la metformine, de la pioglitazone et un inhibiteur de sglt-2

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2877269A (en) 1956-04-17 1959-03-10 Wm S Merrell Co Guanyl substituted triphenylethanes, triphenylethylenes and benzalfluorenes
US2868779A (en) 1956-08-28 1959-01-13 Olin Mathieson Process for the purification of streptomycin
DE1039198B (de) 1956-12-12 1958-09-18 Farmaceutici Italia Verfahren zur Herstellung und Gewinnung von Antibiotika
US2928829A (en) 1959-08-31 1960-03-15 Ciba Pharm Prod Inc Alkyleneimino-lower alkyl-guanidines
BE612362A (fr) 1961-01-06 1962-05-02 Parke Davis & Co Composés de la guanidine et procédés pour les préparer.
BE757496A (fr) 1969-10-14 1971-03-16 Ono Pharmaceutical Co Nouveaux esters phenyles de l'acide guanidinocaproique et leur production
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
JPS5512411B2 (fr) 1974-03-12 1980-04-02
US4126672A (en) 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4207890A (en) 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
FI63335B (fi) 1979-02-02 1983-02-28 Orion Yhtymae Oy Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne
US4228156A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228155A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4357469A (en) 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
SE460667B (sv) 1979-09-20 1989-11-06 Nippon Chemiphar Co Cyklohexankarboxylsyraderivat, foerfarande foer framstaellning daerav samt naemnda derivat foer terapeutisk anvaendning
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US4465851A (en) 1981-01-22 1984-08-14 Nippon Chemiphar Co., Ltd. Guanidinocyclohexanecarboxylic acid derivatives
JPS5862152A (ja) 1981-10-08 1983-04-13 Microbial Chem Res Found Ｎ−〔４−（３−アミノプロピル）アミノブチル〕−２−（ω−グアニジノ脂肪酸アミド）−２−ヒドロキシエタンアミドおよびその誘導体ならびにその製造法
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4410512A (en) 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US4410513A (en) 1981-12-28 1983-10-18 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4544500A (en) 1982-04-14 1985-10-01 Scripps Clinic And Research Foundation Synthetic foot and mouth disease antigen
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
JPS6034190A (ja) 1983-08-05 1985-02-21 Microbial Chem Res Found アルフアメニンの高収率製造法
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0150378B1 (fr) 1984-01-23 1990-03-28 Takeda Chemical Industries, Ltd. Dérivés céphem et leur préparation
JPS6133173A (ja) 1984-07-25 1986-02-17 Torii Yakuhin Kk アミジン化合物
DE3678308D1 (de) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4732971A (en) 1985-06-03 1988-03-22 Eli Lilly And Company Synthetic vaccines for foot and mouth disease
US4683291A (en) 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
US4704285A (en) 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
JPS62195323A (ja) 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
FR2594693B1 (fr) 1986-02-24 1990-01-05 Farah Nabil Nouveaux procedes de preparation a partir d'emulsions seches de formes orales solides a liberation modifiee et retardee de leur principes actifs
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4880778A (en) 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
IT1213495B (it) 1986-09-17 1989-12-20 Sigma Tau Ind Farmaceuti Processo per la preparazione dell'alfa-n-[(ipoxatin-9-il)pentilossicarbonil-]arginina
US5374430A (en) 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
EP0275748B1 (fr) 1986-12-15 1992-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux dérivés peptidiques et leur application notamment en thérapeutique
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4880777A (en) 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
US4857508A (en) 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
AU639409B2 (en) 1987-12-10 1993-07-29 La Jolla Cancer Research Foundation Conformationally stabilized cell adhesion peptides
JPH021418A (ja) 1988-03-15 1990-01-05 Toray Ind Inc ３，３’，５，５’―テトラメチルビフェニル―４，４’―ジオールの製造法
JP2873340B2 (ja) 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質ｔａｎ―１０５７，その製造法および用途
ZW6189A1 (en) 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
EP0417165B1 (fr) 1988-05-11 1994-01-26 Polygen Holding Corporation Composes polypeptides ayant une activite de liberation d'hormone de croissance
US4892440A (en) 1988-07-05 1990-01-09 Eveready Flood Control Water backup preventing system and monitoring system therefor
JP2945680B2 (ja) 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5039805A (en) 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
CA2007181C (fr) * 1989-01-06 1998-11-24 Angelo Mario Morella Compose pharmaceutique a liberation continue
US5084466A (en) 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (fr) 1989-02-23 2001-11-20 Thomas Weller Derives de glycine
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5318899A (en) 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
FR2650210B1 (fr) 1989-07-27 1991-10-31 Renault Automation Procede et dispositif de manutention robotise
US5061693A (en) 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0410541A1 (fr) 1989-07-28 1991-01-30 Merck & Co. Inc. Antagonistes des récepteurs fibrinogéniques
EP0410537A1 (fr) 1989-07-28 1991-01-30 Merck & Co. Inc. Antagonistes pour le récepteur du fibrinogène
CA2021952A1 (fr) 1989-07-28 1991-01-29 Ruth F. Nutt Antagonistes des recepteurs du fibrinogene
EP0410540A1 (fr) 1989-07-28 1991-01-30 Merck & Co. Inc. Antagonistes des récepteurs fibrinogéniques
US4952562A (en) 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
NZ235563A (en) 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
NZ235564A (en) 1989-10-13 1993-10-26 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical compositions
US5232704A (en) 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU668386B2 (en) 1992-03-25 1996-05-02 Depomed Systems, Incorporated Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
CA2151044A1 (fr) 1992-12-15 1994-06-23 Terence K. Brunck Nouveaux inhibiteurs pour le facteur xa
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
JP2686215B2 (ja) 1993-04-28 1997-12-08 信越化学工業株式会社 徐放性錠剤
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5690959A (en) 1993-05-29 1997-11-25 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
IL109770A0 (en) 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
GB9505032D0 (en) * 1995-03-13 1995-05-03 Westminster Lab Ltd Improvements in or relating to organic compositions
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5645858A (en) 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
DE19512307A1 (de) 1995-04-01 1996-10-02 Werner Reinig Gerade Leuchtstoffröhre mit eingebautem elektronischen Vorschaltgerät
GB9523752D0 (en) 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DE69831335T3 (de) 1997-06-06 2015-01-15 Depomed, Inc. Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6120803A (en) * 1997-08-11 2000-09-19 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
WO1999029314A1 (fr) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Sels de metformine et procede
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US7657893B2 (en) 2003-04-23 2010-02-02 International Business Machines Corporation Accounting method and logic for determining per-thread processor resource utilization in a simultaneous multi-threaded (SMT) processor
US8901829B2 (en) 2009-09-24 2014-12-02 Cree Led Lighting Solutions, Inc. Solid state lighting apparatus with configurable shunts
IN2012DN05162A (fr) 2009-12-24 2015-10-23 Du Pont
JP2013114731A (ja) 2011-11-30 2013-06-10 Toshiba Corp 半導体記憶装置
US9200999B2 (en) 2013-09-11 2015-12-01 GM Global Technology Operations LLC Method and system for characterizing color variation of a surface

Also Published As

Publication number Publication date
EP1063973B1 (fr) 2016-11-16
AU3182899A (en) 1999-10-11
BR9908911A (pt) 2001-10-02
EP1063973A1 (fr) 2001-01-03
JP2002506812A (ja) 2002-03-05
ID26082A (id) 2000-11-23
WO1999047128A1 (fr) 1999-09-23
EP1063973A4 (fr) 2008-11-19
US6475521B1 (en) 2002-11-05
EA200000968A1 (ru) 2001-06-25
AP2000001885A0 (en) 2000-09-30
CN1203846C (zh) 2005-06-01
CA2320900C (fr) 2009-10-27
AP1224A (en) 2003-11-14
JP4523153B2 (ja) 2010-08-11
EP2332522A3 (fr) 2011-12-07
US6660300B1 (en) 2003-12-09
AU736951C (en) 2003-02-20
KR100620935B1 (ko) 2006-09-13
KR20010041958A (ko) 2001-05-25
EA003101B1 (ru) 2002-12-26
NZ506202A (en) 2003-10-31
CN1295467A (zh) 2001-05-16
EP2332522A2 (fr) 2011-06-15
AU736951B2 (en) 2001-08-09
CA2320900A1 (fr) 1999-09-23

Similar Documents

Publication Publication Date Title
AU736951C (en) Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6068859A (en) Controlled-release dosage forms of Azithromycin
EP1558220B1 (fr) Compositions orales pour le traitement du diabete
EP0591424B1 (fr) Diltiazem se presentant sous une forme a liberation prolongee
US20020051814A1 (en) Composition for the treatment and prevention of ischemic events
WO1994010983A1 (fr) Preparation pharmaceutique perorale liberable dans le tube digestif inferieur
SK455990A3 (en) Pharmaceutical delivery systems and methods of preparation thereof
JP2004523510A (ja) スペーストドラッグデリバリーシステム
JP2002533380A (ja) 多孔性粒子を含む剤形
CA2379595A1 (fr) Formulations orales a liberation controlee
JP3282832B2 (ja) 持続性錠剤
JP3122478B2 (ja) 下部消化管放出型経口製剤
JP2727009B2 (ja) 持続性製剤
MXPA00008579A (en) Biphasic controlled release delivery system for high solubility pharmaceuticals and method
MXPA96002863A (en) Pharmaceutical preparation in the form of a liberable coated capsule at the bottom of the digest tract